HIV-1 reverse transcriptase and antiviral drug resistance. Part 2

Current Opinion in Virology

Volumn 3, Issue 2, 2013, Pages 119-128

  Das, Kalyan ^a   Arnold, Eddy ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRIMER DNA; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG BINDING; GENE MUTATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

EID: 84880058866     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.03.014     Document Type: Review

References (84)

1. Huang H, Chopra R, Verdine GL, Harrison SC: Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282:1669-1675.
2. Sarafianos SG, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH, Arnold E: Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with b-branched amino acids. Proc Natl Acad Sci U S A 1999, 96:10027-10032.
3. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E: Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001, 75:4771-4779.
4. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC: Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997, 41:757-762.
5. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, Tisdale M, Larder B: Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis 2000, 181:912-920.
6. Margot NA, Lu B, Cheng A, Miller MD: Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006, 7:442-450.
7. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG, Wainberg MA: Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009, 83:2029-2033.
8. Das K, Bandwar RP, White KL, Feng JY, Sarafianos SG, Tuske S, Tu X, Clark AD Jr, Boyer PL, Hou X et al.: Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 2009, 284:35092-35100.
9. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G et al.: HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000, 14:163-171.
10. Stone C, Ait-Khaled M, Craig C, Griffin P, Tisdale M: Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother 2004, 48:1413-1415.
11. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
12. Martin JL, Wilson JE, Haynes RL, Furman PA: Mechanism of resistance of human immunodeficiency virus type 1 to 20,30-dideoxyinosine. Proc Natl Acad Sci U S A 1993, 90:6135-6139.
13. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R et al.: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A 1995, 92:2398-2402.
14. Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H: Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Infect Dis 1998, 177:1506-1513.
15. Kaushik N, Talele TT, Pandey PK, Harris D, Yadav PN, Pandey VN: Role of glutamine 151 of human immunodeficiency virus type-1 reverse transcriptase in substrate selection as assessed by site-directed mutagenesis. Biochemistry 2000, 39:2912-2920.
16. Deval J, Selmi B, Boretto J, Egloff MP, Guerreiro C, Sarfati S, Canard B: The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alphaboranophosphate nucleotide analogues. J Biol Chem 2002, 277:42097-42104.
17. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, Selmi B, Boretto J, Canard B: Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004, 279:509-516.
18. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H: Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J Virol 1999, 73:5356-5363.
19. Ray AS, Basavapathruni A, Anderson KS: Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 2002, 277:40479-40490.
20. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
21. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA: Phenotypic mechanism of HIV-1 resistance to 30-azido-30-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998, 37:15908-15917.
22. Meyer PR, Matsuura SE, So AG, Scott WA: Unblocking of chainterminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A 1998, 95:13471-13476.
23. Tu X, Das K, Han Q, Bauman JD, Clark AD Jr, Hou X, Frenkel YV, Gaffney BL, Jones RA, Boyer PL et al.: Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol 2010, 17:1202-1209.
24. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA: A mechanism of AZT resistance: an increase in nucleotidedependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999, 4:35-43.
25. Boyer PL, Sarafianos SG, Arnold E, Hughes SH: Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001, 75:4832-4842.
26. Scott WA: Structures of reverse transcriptase pre-and postexcision complexes shed new light on HIV-1 AZT resistance. Viruses 2011, 3:20-25.
27. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992, 165:105-110.
28. Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B: Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. Virology 2001, 283:294-305.
29. Jiang LJ, Maret W, Vallee BL: The ATP-metallothionein complex. Proc Natl Acad Sci U S A 1998, 95:9146-9149.
30. Harrigan PR, Bloor S, Larder BA: Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998, 72:3773-3778.
31. Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR: Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 2006, 80:7020-7027.
32. Arion D, Parniak MA: HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resist Updat 1999, 2:91-95.
33. Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, Gastaut JA, Gallais H, Moreau J, Fantini J: Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999, 37:4099-4106.
34. Garcia-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W: Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol 2004, 78:7545-7552.
35. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A, Larder BA: Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996, 70:5930-5934.
36. Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ: An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 30-azido-30- deoxythymidine. J Virol 1996, 70:8010-8018.
37. Mas A, Parera M, Briones C, Soriano V, Martinez MA, Domingo E, Menendez-Arias L: Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J 2000, 19:5752-5761.
38. Boyer PL, Sarafianos SG, Arnold E, Hughes SH: Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol 2002, 76:9143-9151.
39. Meyer PR, Lennerstrand J, Matsuura SE, Larder BA, Scott WA: Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J Virol 2003, 77:3871-3877.
40. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, Swaminathan S, Miller MD: Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analogassociated mutations. Antimicrob Agents Chemother 2004, 48:992-1003.
41. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, Lane HC: Relative replication fitness of a high-level 30-azido-30-deoxythymidine- resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr!Gly) at codon 69. J Virol 2000, 74:10958-10964.
42. Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH: Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J Virol 2004, 78:9987-9997.
43. Deval J, Powdrill MH, D'Abramo CM, Cellai L, Gotte M: Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2007, 51:2920-2928.
44. Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K: NTP-mediated nucleotide excision activity of hepatitis C virus RNAdependent RNA polymerase. Proc Natl Acad Sci U S A 2013, 110:E348-E357.
45. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, Shen L, Siliciano RF: A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 2012, 18:446-451.
46. Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia-Cancio PV, Zolopa A, Robbins GK, Kagan R et al.: Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother 2012, 56:2305-2313.
47. Delaunay C, Brun-Vezinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D: Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005, 79:9572-9578.
48. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK: Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002, 46:3437-3446.
49. Deval J, Navarro JM, Selmi B, Courcambeck J, Boretto J, Halfon P, Garrido-Urbani S, Sire J, Canard B: A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem 2004, 279:25489-25496.
50. Sharma PL, Nurpeisov V, Lee K, Skaggs S, Di San Filippo CA, Schinazi RF: Replication-dependent 65RK reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65!R + L74V. Virology 2004, 321:222-234.
51. McColl DJ, Chappey C, Parkin NT, Miller MD: Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther 2008, 13:189-197.
52. Miranda LR, Gotte M, Liang F, Kuritzkes DR: The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 2005, 49:2648-2656.
53. Van Laethem K, Pannecouque C, Vandamme AM: Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways. Infect Genet Evol 2007, 7:600-603.
54. Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, Sakagami Y, Oka S, Singh K, Sarafianos SG: K70Q adds highlevel tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS ONE 2011, 6:e16242.
55. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, Lengauer T, Selbig J, Vandamme AM, Korn K et al.: Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003, 47:3478-3484.
56. White KL, Margot NA, Ly JK, Chen JM, Ray AS, Pavelko M, Wang R, McDermott M, Swaminathan S, Miller MD: A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005, 19:1751-1760.
57. Parikh UM, Bacheler L, Koontz D, Mellors JW: The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006, 80:4971-4977.
58. Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW: Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2007, 51:48-53.
59. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
60. Spence RA, Kati WM, Anderson KS, Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267:988-993.
61. Rittinger K, Divita G, Goody RS: Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci U S A 1995, 92:8046-8049.
62. Abbondanzieri EA, Bokinsky G, Rausch JW, Zhang JX, Le Grice SF, Zhuang X: Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 2008, 453:184-189.
63. Liu S, Abbondanzieri EA, Rausch JW, Le Grice SF, Zhuang X: Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. Science 2008, 322:1092-1097.
64. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure at 3.5 A ° resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
65. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D et al.: High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995, 2:293-302.
66. Xia Q, Radzio J, Anderson KS, Sluis-Cremer N: Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci 2007, 16:1728-1737.
67. Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL et al.: Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 1996, 264:1085-1100.
68. Das K, Martinez SE, Bauman JD, Arnold E: HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism. Nat Struct Mol Biol 2012, 19:253-259.
69. Das K, Sarafianos SG, Clark AD Jr, Boyer PL, Hughes SH, Arnold E: Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J Mol Biol 2007, 365:77-89.
70. Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Rosner M, Rubsamen-Waigmann H, Kaiser R, Wichers M, Schneweis KE et al.: Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1995, 39:2253-2257.
71. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM: Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003, 77:1512-1523.
72. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA: Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011, 85:11300-11308.
73. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K et al.: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 2012, 60:33-42.
74. Hsiou Y, Ding J, Das K, Clark AD Jr, Hughes SH, Arnold E: Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 4:853-860.
75. Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E: High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A 2008, 105:1466-1471.
76. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL: Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues. J Med Chem 2004, 47:2389-2392.
77. Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK: Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J 2006, 273:3850-3860.
78. Das K, Bauman JD, Rim AS, Dharia C, Clark AD Jr, Camarasa MJ, Balzarini J, Arnold E: Crystal structure of tert- butyldimethylsilylspiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J Med Chem 2011, 54:2727-2737.
79. Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z et al.: Biochemical mechanism of HIV-1 resistance to rilpivirine. J Biol Chem 2012, 287:38110-38123.
80. Selmi B, Deval J, Alvarez K, Boretto J, Sarfati S, Guerreiro C, Canard B: The Y181C substitution in 30-azido-30-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 30-azido-30-deoxythymidine 50-monophosphateterminated primer. J Biol Chem 2003, 278:40464-40472.
81. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM et al.: Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305:1327-1335.
82. Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I: Vaginal rings for delivery of HIV microbicides. Int J Womens Health 2012, 4:595-605.
83. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD: 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011, 19:156-164.
84. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT et al.: Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378:238-246.